Vertex Pharmaceuticals (VRTX) stock is in focus after regulators expanded US approval of its gene therapy CASGEVY to children as young as 2 with sickle cell disease or transfusion dependent beta thalassemia.

The latest FDA approval comes after a volatile few sessions for Vertex Pharmaceuticals, with the share price down 9.32% over the past week but showing a 30 day share price return of 7.94% and a 5 year total shareholder return of 141.04%. This suggests longer term momentum remains intact even as investors reassess recent news and the pending Crinetics deal.

If Vertex’s gene therapy progress has your attention, it may be a good time to look wider in healthcare and see what else is gaining traction through the 40 healthcare AI stocks

After Vertex Pharmaceuticals fell over the past week yet still trades about 16% below the average analyst target and at an indicated intrinsic discount of around 42%, is the market being sensibly cautious or too skeptical of its pipeline and deals?

Most Popular Narrative: 12.3% Undervalued

Based on the most followed narrative, Vertex Pharmaceuticals’ fair value of $547.72 sits above the recent close of $480.25, framing the current discount through a long term earnings and pipeline lens.

Vertex Pharmaceuticals Future Earnings and Revenue Growth

Assumptions
How have these above catalysts been quantified?

• Analysts are assuming Vertex Pharmaceuticals's revenue will grow by 10.0% annually over the next 3 years.

• Analysts assume that profit margins will increase from 32.9% today to 37.0% in 3 years time.

• Analysts expect earnings to reach $5.9 billion (and earnings per share of $22.56) by about March 2029, up from $4.0 billion today. However, there is a considerable amount of disagreement amongst the analysts with the most bullish expecting $8.6 billion in earnings, and the most bearish expecting $3.3 billion.

• In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 28.0x on those 2029 earnings, down from 29.2x today. This future PE is greater than the current PE for the US Biotechs industry at 16.7x.

• Analysts expect the number of shares outstanding to decline by 1.08% per year for the next 3 years.

• To value all of this in today's terms, we will use a discount rate of 7.1%, as per the Simply Wall St company report.

Want to see what has to happen for that fair value to hold up? The story leans heavily on compounding revenue, rising margins and a premium earnings multiple. Curious how much optimism is baked into those assumptions? The full narrative lays out the numbers in black and white.

Result: Fair Value of $547.72 (UNDERVALUED)

However, the Vertex Pharmaceuticals story can change quickly if cystic fibrosis cash flows face sharper competition or if key gene editing and renal trials run into regulatory setbacks.

Another View: Vertex Pharmaceuticals Through the Earnings Multiple Lens

The first fair value view for Vertex Pharmaceuticals leans on long term earnings and discounted cash flows, yet the current P/E ratio of 28.1x tells a different story. It sits well above the US Biotechs industry at 17.4x and even slightly above the 27.8x fair ratio.

At the same time, that 28.1x P/E is well below the 44.9x peer average. Investors weighing Vertex Pharmaceuticals are looking at a stock that screens expensive against the sector, closer to fairly priced against its own fair ratio, and cheaper than peers. Is that a safety margin or a warning sign around expectations.

Next Steps

With sentiment on Vertex Pharmaceuticals split between cautious and optimistic, it helps to see the details first hand. Move quickly and weigh the potential benefits for yourself by reviewing the 3 key rewards

Looking for more investment ideas beyond Vertex Pharmaceuticals?

If Vertex Pharmaceuticals is on your radar, do not stop there. A broader watchlist can help you spot opportunities that fit different goals and risk levels.

• Target powerful long term growth potential by reviewing companies flagged in the screener containing 20 high quality undiscovered gems.
• Prioritize stability and capital preservation by checking stocks in the 80 resilient stocks with low risk scores.
• Strengthen your portfolio’s foundation by focusing on companies featured in the solid balance sheet and fundamentals stocks screener (47 results).

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.